• Association between plasma phospholipid saturated fatty acids and metabolic markers of lipid, hepatic, inflammation and glycaemic pathways in eight European countries: a cross-sectional analysis in the EPIC-InterAct study.

      Zheng, Ju-Sheng; Sharp, Stephen J; Imamura, Fumiaki; Koulman, Albert; Schulze, Matthias B; Ye, Zheng; Griffin, Jules; Guevara, Marcela; Huerta, José María; Kröger, Janine; Sluijs, Ivonne; Agudo, Antonio; Barricarte, Aurelio; Boeing, Heiner; Colorado-Yohar, Sandra; Dow, Courtney; Dorronsoro, Miren; Dinesen, Pia T; Fagherazzi, Guy; Franks, Paul W; Feskens, Edith J M; Kühn, Tilman; Katzke, Verena Andrea; Key, Timothy J; Khaw, Kay-Tee; de Magistris, Maria Santucci; Mancini, Francesca Romana; Molina-Portillo, Elena; Nilsson, Peter M; Olsen, Anja; Overvad, Kim; Palli, Domenico; Quirós, Jose Ramón; Rolandsson, Olov; Ricceri, Fulvio; Spijkerman, Annemieke M W; Slimani, Nadia; Tagliabue, Giovanna; Tjonneland, Anne; Tumino, Rosario; van der Schouw, Yvonne T; Langenberg, Claudia; Riboli, Elio; Forouhi, Nita G; Wareham, Nicholas J (2017-11-17)
      Accumulating evidence suggests that individual circulating saturated fatty acids (SFAs) are heterogeneous in their associations with cardio-metabolic diseases, but evidence about associations of SFAs with metabolic markers of different pathogenic pathways is limited. We aimed to examine the associations between plasma phospholipid SFAs and the metabolic markers of lipid, hepatic, glycaemic and inflammation pathways.
    • Lifetime and baseline alcohol intakes and risk of pancreatic cancer in the European Prospective Investigation into Cancer and Nutrition study.

      Naudin, Sabine; Li, Kuanrong; Jaouen, Tristan; Assi, Nada; Kyrø, Cecilie; Tjønneland, Anne; Overvad, Kim; Boutron-Ruault, Marie-Christine; Rebours, Vinciane; Védié, Anne-Laure; Boeing, Heiner; Kaaks, Rudolf; Katzke, Verena; Bamia, Christina; Naska, Androniki; Trichopoulou, Antonia; Berrino, Franco; Tagliabue, Giovanna; Palli, Domenico; Panico, Salvatore; Tumino, Rosario; Sacerdote, Carlotta; Peeters, Petra H; Bueno-de-Mesquita, Bas; Weiderpass Vainio, Elisabete; Gram, Inger Torhild; Skeie, Guri; Chirlaque, Maria-Dolores; Rodríguez-Barranco, Miguel; Barricarte, Aurelio; Quirós, Jose Ramón; Dorronsoro, Miren; Johansson, Ingegerd; Sund, Malin; Sternby, Hanna; Bradbury, Kathryn E; Wareham, Nick; Riboli, Elio; Gunter, Marc; Brennan, Paul; Duell, Eric J; Ferrari, Pietro (2018-03-09)
      Recent evidence suggested a weak relationship between alcohol consumption and pancreatic cancer (PC) risk. In this study, the association between lifetime and baseline alcohol intakes and the risk of PC was evaluated, including the type of alcoholic beverages and potential interaction with smoking. Within the European Prospective Investigation into Cancer and Nutrition (EPIC) study, 1,283 incident PC (57% women) were diagnosed from 476,106 cancer-free participants, followed up for 14 years. Amounts of lifetime and baseline alcohol were estimated through lifestyle and dietary questionnaires, respectively. Cox proportional hazard models with age as primary time variable were used to estimate PC hazard ratios (HR) and their 95% confidence interval (CI). Alcohol intake was positively associated with PC risk in men. Associations were mainly driven by extreme alcohol levels, with HRs comparing heavy drinkers (>60 g/day) to the reference category (0.1-4.9 g/day) equal to 1.77 (95% CI: 1.06, 2.95) and 1.63 (95% CI: 1.16, 2.29) for lifetime and baseline alcohol, respectively. Baseline alcohol intakes from beer (>40 g/day) and spirits/liquors (>10 g/day) showed HRs equal to 1.58 (95% CI: 1.07, 2.34) and 1.41 (95% CI: 1.03, 1.94), respectively, compared to the reference category (0.1-2.9 g/day). In women, HR estimates did not reach statistically significance. The alcohol and PC risk association was not modified by smoking status. Findings from a large prospective study suggest that baseline and lifetime alcohol intakes were positively associated with PC risk, with more apparent risk estimates for beer and spirits/liquors than wine intake. This article is protected by copyright. All rights reserved.
    • Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study.

      Duell, Eric J; Lujan-Barroso, Leila; Sala, Núria; Deitz McElyea, Samantha; Overvad, Kim; Tjonneland, Anne; Olsen, Anja; Weiderpass, Elisabete; Busund, Lill-Tove; Moi, Line; Muller, David; Vineis, Paolo; Aune, Dagfinn; Matullo, Giuseppe; Naccarati, Alessio; Panico, Salvatore; Tagliabue, Giovanna; Tumino, Rosario; Palli, Domenico; Kaaks, Rudolf; Katzke, Verena A; Boeing, Heiner; Bueno-de-Mesquita, H B As; Peeters, Petra H; Trichopoulou, Antonia; Lagiou, Pagona; Kotanidou, Anastasia; Travis, Ruth C; Wareham, Nick; Khaw, Kay-Tee; Ramon Quiros, Jose; Rodríguez-Barranco, Miguel; Dorronsoro, Miren; Chirlaque, María-Dolores; Ardanaz, Eva; Severi, Gianluca; Boutron-Ruault, Marie-Christine; Rebours, Vinciane; Brennan, Paul; Gunter, Marc; Scelo, Ghislaine; Cote, Greg; Sherman, Stuart; Korc, Murray (2017-09-01)
      Noninvasive biomarkers for early pancreatic ductal adenocarcinoma (PDAC) diagnosis and disease risk stratification are greatly needed. We conducted a nested case-control study within the Prospective Investigation into Cancer and Nutrition (EPIC) cohort to evaluate prediagnostic microRNAs (miRs) as biomarkers of subsequent PDAC risk. A panel of eight miRs (miR-10a, -10b, -21-3p, -21-5p, -30c, -106b, -155 and -212) based on previous evidence from our group was evaluated in 225 microscopically confirmed PDAC cases and 225 controls matched on center, sex, fasting status and age/date/time of blood collection. MiR levels in prediagnostic plasma samples were determined by quantitative RT-PCR. Logistic regression was used to model levels and PDAC risk, adjusting for covariates and to estimate area under the receiver operating characteristic curves (AUC). Plasma miR-10b, -21-5p, -30c and -106b levels were significantly higher in cases diagnosed within 2 years of blood collection compared to matched controls (all p-values <0.04). Based on adjusted logistic regression models, levels for six miRs (miR-10a, -10b, -21-5p, -30c, -155 and -212) overall, and for four miRs (-10a, -10b, -21-5p and -30c) at shorter follow-up time between blood collection and diagnosis (≤5 yr, ≤2 yr), were statistically significantly associated with risk. A score based on the panel showed a linear dose-response trend with risk (p-value = 0.0006). For shorter follow-up (≤5 yr), AUC for the score was 0.73, and for individual miRs ranged from 0.73 (miR-212) to 0.79 (miR-21-5p).